USD 192.06
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ALX | 0.6 | 3.8 | -4.4 | -18.2 | -18.7 | -13.9 | -25.2 | -45.0 | -58.2 | 773 |
| S&P 500 | 1.0 | 3.7 | 2.2 | 2.3 | 8.9 | 23.9 | 32.3 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ALX |
| name | Alexander's, Inc. |
| price | 192.06 |
| changes percentage | 0.6446 |
| change | 1.23 |
| day low | 190.6 |
| day high | 195.2 |
| year high | 251.63 |
| year low | 184.76 |
| market cap | 980906117 |
| price avg 50 | 211.1282 |
| price avg 200 | 221.15105 |
| exchange | NYSE |
| volume | 16218 |
| avg volume | 12391 |
| open | 190.6 |
| previous close | 190.83 |
| eps | 9.26 |
| pe | 20.74 |
| earnings announcement | 2025-02-10T13:30:00.000+0000 |
| shares outstanding | 5107290 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000003499 | |||
| revenue | 224962000 | 205814000 | 9.30 |
| gross profit | 123752000 | 115368000 | 7.27 |
| gross profit ratio | 0.55 | 0.56 | -1.86 |
| research and development expenses | 0 | 0.28 | -100.00 |
| operating expenses | 6341000 | 126349000 | -94.98 |
| interest income | 22245000 | 6769000 | 228.63 |
| interest expense | 58297000 | 28602000 | 103.82 |
| ebitda | 117411000 | 117688000 | -0.24 |
| ebitdaratio | 0.52 | 0.57 | -8.73 |
| operating income | 117411000 | 86234000 | 36.15 |
| operating income ratio | 0.52 | 0.42 | 24.56 |
| net income | 102413000 | 29030000 | 252.78 |
| net income ratio | 0.46 | 0.14 | 222.76 |
| eps | 19.97 | 5.66 | 252.83 |
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000003499 | |||
| revenue | 55675000 | 53392000 | 4.28 |
| gross profit | 29229000 | 19094000 | 53.08 |
| gross profit ratio | 0.52 | 0.36 | 46.80 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 1423000 | 33892000 | -95.80 |
| interest income | 6105000 | 7054000 | -13.45 |
| interest expense | 19261000 | 16219000 | 18.76 |
| ebitda | 33911000 | 26242000 | 29.22 |
| ebitdaratio | 0.61 | 0.49 | 23.93 |
| operating income | 27806000 | 17545000 | 58.48 |
| operating income ratio | 0.5 | 0.33 | 51.99 |
| net income | 6678000 | 8380000 | -20.31 |
| net income ratio | 0.12 | 0.16 | -23.58 |
| eps | 1.3 | 1.63 | -20.25 |
Revenue Growth: revenue increased to 56 million in 2024Q3 from 53 million in 2024Q2 representing a change of 4.28%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 29 million in 2024Q3 from 19 million in 2024Q2 representing a change of 53.08%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 1 million in 2024Q3 from 34 million in 2024Q2 representing a change of -95.8%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 34 million in 2024Q3 from 26 million in 2024Q2 representing a change of 29.22%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 28 million in 2024Q3 from 18 million in 2024Q2 representing a change of 58.48%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income decreased to 7 million in 2024Q3 from 8 million in 2024Q2 representing a change of -20.31%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 1.3 in 2024Q3 from 1.3 in 2024Q2 representing a change of -20.25%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000003499 | |||
| total assets | 1403680000 | 1397776000 | 0.42 |
| total liabilities | 1166023000 | 1161277000 | 0.41 |
| total equity | 237657000 | 866175000 | -72.56 |
| cash and cash equivalents | 531855000 | 194933000 | 172.84 |
| short term investments | 0 | 266963000 | -100.00 |
| long term investments | 0 | 29351000 | -100.00 |
| total current assets | 683919000 | 613643000 | 11.45 |
| total non current assets | 719761000 | 784133000 | -8.21 |
| total current liabilities | 52465000 | 49586000 | 5.81 |
| total non current liabilities | 1113558000 | 1111691000 | 0.17 |
| common stock | 5173000 | 5173000 | 0.00 |
| retained earnings | 182336000 | 172243000 | 5.86 |
| total debt | 1113003000 | 1091051000 | 2.01 |
Total Assets: Total Assets increased to 1,404 million in 2023 from 1,398 million in 2022 representing a change of 0.42%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 532 million in 2023 from 195 million in 2022 representing a change of 172.84%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 684 million in 2023 from 614 million in 2022 representing a change of 11.45%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 182 million in 2023 from 172 million in 2022 representing a change of 5.86%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 1,166 million in 2023 from 1,161 million in 2022 representing a change of 0.41%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 238 million in 2023 from 866 million in 2022 representing a change of -72.56%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 0 million in 2023 from 267 million in 2022 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 52 million in 2023 from 50 million in 2022 representing a change of 5.81%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 1,113 million in 2023 from 1,091 million in 2022 representing a change of 2.01%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000003499 | |||
| total assets | 1364969000 | 1480750000 | -7.82 |
| total liabilities | 1174280000 | 1268230000 | -7.41 |
| total equity | 190689000 | 212520000 | -10.27 |
| cash and cash equivalents | 354817000 | 524376999 | -32.34 |
| short term investments | 0 | 12800000 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 514910000 | 642770000 | -19.89 |
| total non current assets | 850059000 | 837980000 | 1.44 |
| total current liabilities | 51386000 | 51401000 | -0.03 |
| total non current liabilities | 1122894000 | 1216829000 | -7.72 |
| common stock | 5173000 | 5173000 | 0.00 |
| retained earnings | 144226000 | 160649000 | -10.22 |
| total debt | 1101596000 | 1082012000 | 1.81 |
Total Assets: Total Assets decreased to 1,365 million in 2024Q3 from 1,481 million in 2024Q2 representing a change of -7.82%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 191 million in 2024Q3 from 213 million in 2024Q2 representing a change of -10.27%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 355 million in 2024Q3 from 524 million in 2024Q2 representing a change of -32.34%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2024Q3 from 13 million in 2024Q2 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 515 million in 2024Q3 from 643 million in 2024Q2 representing a change of -19.89%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to 144 million in 2024Q3 from 161 million in 2024Q2 representing a change of -10.22%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 1,102 million in 2024Q3 from 1,082 million in 2024Q2 representing a change of 1.81%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 1,174 million in 2024Q3 from 1,268 million in 2024Q2 representing a change of -7.41%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 51 million in 2024Q3 from 51 million in 2024Q2 representing a change of -0.03%. This indicates a lower short-term debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000003499 | |||
| net change in cash | 338499000 | -269027000 | 225.82 |
| operating cash flow | 109111000 | 102549000 | 6.40 |
| free cash flow | 109111000 | 102549000 | 6.40 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 34605000 | 31454000 | 10.02 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 450000 | 450000 | 0.00 |
| accounts payables | 3263000 | 3141000 | 3.88 |
| inventory | 0 | -1680000 | 100.00 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | 321812000 | -279266000 | 215.23 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | -364238000 | 100.00 |
| dividends paid | -92320000 | -92264000 | -0.06 |
| net cash used provided by financing activities | -92424000 | -92310000 | -0.12 |
| cash at end of period | 552977000 | 214478000 | 157.82 |
| accounts receivables | 0 | 1680000 | -100.00 |
| cash at beginning of period | 214478000 | 483505000 | -55.64 |
Net Change in Cash: Net Change in Cash increased to 338 million in 2023 from -269 million in 2022 representing a change of 225.82%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 109 million in 2023 from 103 million in 2022 representing a change of 6.4%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 109 million in 2023 from 103 million in 2022 representing a change of 6.4%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2023 from 2 million in 2022 representing a change of -100.0%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Accounts Payables: The absolute value of Accounts Payables increased to 3 million in 2023 from 3 million in 2022 representing a change of 3.88%. This indicates that the company has increased its outstanding obligations to its suppliers.
Dividends Paid: Dividends Paid decreased to -92 million in 2023 from -92 million in 2022 representing a change of -0.06%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000003499 | |||
| operating cash flow | -5031000 | 11502000 | -143.74 |
| free cash flow | -5031000 | 11502000 | -143.74 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 7972000 | 8697000 | -8.34 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 450000 | 0 | NaN |
| accounts receivables | -674000 | 327000 | -306.12 |
| accounts payables | -5447000 | 5694000 | -195.66 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | -3654000 | -304000 | -1101.97 |
| debt repayment | -90000000 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | -23101000 | -23088000 | -0.06 |
| net cash used provided by financing activities | -118516000 | -34220000 | -246.34 |
| net change in cash | -127200999 | -23022001 | -452.52 |
| cash at end of period | 397176000 | 524376999 | -24.26 |
| cash at beginning of period | 524376999 | 547399000 | -4.21 |
Net Change in Cash: Net Change in Cash decreased to -127 million in 2024Q3 from -23 million in 2024Q2 representing a change of -452.52%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -5 million in 2024Q3 from 12 million in 2024Q2 representing a change of -143.74%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -5 million in 2024Q3 from 12 million in 2024Q2 representing a change of -143.74%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Dividends Paid: Dividends Paid decreased to -23 million in 2024Q3 from -23 million in 2024Q2 representing a change of -0.06%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
Accounts Payables: The absolute value of Accounts Payables decreased to 5 million in 2024Q3 from 6 million in 2024Q2 representing a change of -195.66%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -1 million in 2024Q3 from 0 million in 2024Q2 representing a change of -306.12%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q4 2023 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 43.86 | 40.15 | 9.23 |
| net income per share | 19.97 | 5.66 | 252.56 |
| operating cash flow per share | 21.27 | 20.01 | 6.33 |
| free cash flow per share | 21.27 | 20.01 | 6.33 |
| cash per share | 103.69 | 90.11 | 15.07 |
| book value per share | 46.33 | 46.14 | 0.43 |
| tangible book value per share | 46.33 | 318.81 | -85.47 |
| shareholders equity per share | 46.33 | 46.14 | 0.43 |
| interest debt per share | 228.35 | 218.42 | 4.55 |
| market cap | 1095471008.1 | 1128049566 | -2.89 |
| enterprise value | 1676619008.1 | 2024167566 | -17.17 |
| pe ratio | 10.7 | 38.86 | -72.47 |
| price to sales ratio | 4.87 | 5.48 | -11.15 |
| pocfratio | 10.04 | 11.0 | -8.73 |
| pfcf ratio | 10.04 | 11.0 | -8.73 |
| pb ratio | 4.61 | 4.77 | -3.36 |
| ptb ratio | 4.61 | 4.77 | -3.36 |
| ev to sales | 7.45 | 9.83 | -24.22 |
| enterprise value over ebitda | 14.28 | 17.2 | -16.97 |
| ev to operating cash flow | 15.37 | 19.74 | -22.15 |
| ev to free cash flow | 15.37 | 19.74 | -22.15 |
| earnings yield | 0.09 | 0.03 | 263.27 |
| free cash flow yield | 0.1 | 0.09 | 9.56 |
| debt to equity | 4.68 | 4.61 | 1.51 |
| debt to assets | 0.79 | 0.78 | 1.58 |
| net debt to ebitda | 4.95 | 7.61 | -35.00 |
| current ratio | 13.04 | 12.38 | 5.34 |
| interest coverage | 2.01 | 3.01 | -33.20 |
| income quality | 1.07 | 1.78 | -40.12 |
| dividend yield | 0.08 | 0.08 | 3.04 |
| payout ratio | 0.9 | 3.18 | -71.64 |
| sales general and administrative to revenue | 0.03 | 0.03 | -4.99 |
| research and ddevelopement to revenue | 0 | 0.0 | -100.00 |
| intangibles to total assets | 0 | -1 | 100.00 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0.0 | 0.0 | -8.51 |
| graham number | 144.27 | 76.67 | 88.17 |
| roic | 0.09 | 0.03 | 169.54 |
| return on tangible assets | 0.07 | 0.01 | 602.60 |
| graham net net | -104.49 | -119.96 | 12.89 |
| working capital | 631454000 | 564057000 | 11.95 |
| tangible asset value | 237657000 | 1634275000 | -85.46 |
| net current asset value | -482104000 | -547634000 | 11.97 |
| invested capital | 1299693000 | -815222000 | 259.43 |
| average receivables | 131572000 | 137022000 | -3.98 |
| average payables | 50267500 | 46733000 | 7.56 |
| average inventory | -14675500 | -18448000 | 20.45 |
| days sales outstanding | 212.45 | 234.45 | -9.38 |
| days payables outstanding | 186.63 | 196.87 | -5.20 |
| days of inventory on hand | 0 | -118.45 | 100.00 |
| receivables turnover | 1.72 | 1.56 | 10.36 |
| payables turnover | 1.96 | 1.85 | 5.49 |
| inventory turnover | 0 | -3.08 | 100.00 |
| roe | 0.43 | 0.12 | 251.06 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) increased to 0.43 on 2023-12-31 from 0.12 on 2022-12-31, representing a change of 251.06%. Suggesting the company has been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 10.70 on 2023-12-31 from 38.86 on 2022-12-31, representing a change of -72.47%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 13.04 on 2023-12-31 from 12.38 on 2022-12-31, representing a change of 5.34%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 4.68 on 2023-12-31 from 4.61 on 2022-12-31, representing a change of 1.51%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. A ratio of 2.0 or higher is usually considered risky.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ALX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 10.85 | 10.4 | 4.24 |
| net income per share | 1.3 | 1.63 | -20.34 |
| operating cash flow per share | -0.98 | 2.24 | -143.73 |
| free cash flow per share | -0.98 | 2.24 | -143.73 |
| cash per share | 69.12 | 104.67 | -33.97 |
| book value per share | 37.15 | 41.41 | -10.30 |
| tangible book value per share | 37.15 | 41.41 | -10.30 |
| shareholders equity per share | 37.15 | 41.41 | -10.30 |
| interest debt per share | 218.34 | 214.0 | 2.03 |
| market cap | 1244163300.24 | 1113263500.86 | 11.76 |
| enterprise value | 1990942300.24 | 1670898501.86 | 19.15 |
| pe ratio | 46.58 | 33.21 | 40.24 |
| price to sales ratio | 22.35 | 20.85 | 7.18 |
| pocfratio | -247.3 | 96.79 | -355.50 |
| pfcf ratio | -247.3 | 96.79 | -355.50 |
| pb ratio | 6.52 | 5.24 | 24.55 |
| ptb ratio | 6.52 | 5.24 | 24.55 |
| ev to sales | 35.76 | 31.29 | 14.27 |
| enterprise value over ebitda | 58.71 | 63.67 | -7.79 |
| ev to operating cash flow | -395.73 | 145.27 | -372.41 |
| ev to free cash flow | -395.73 | 145.27 | -372.41 |
| earnings yield | 0.01 | 0.01 | -28.69 |
| free cash flow yield | -0.0 | 0.01 | -139.14 |
| debt to equity | 5.78 | 5.09 | 13.47 |
| debt to assets | 0.81 | 0.73 | 10.45 |
| net debt to ebitda | 22.02 | 21.25 | 3.63 |
| current ratio | 10.02 | 12.51 | -19.87 |
| interest coverage | 1.44 | 1.08 | 33.45 |
| income quality | -0.75 | 1.37 | -154.89 |
| dividend yield | 0.02 | 0.02 | -10.47 |
| payout ratio | 3.46 | 2.76 | 25.56 |
| sales general and administrative to revenue | 0.03 | 0.03 | -11.90 |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0.01 | 0 | NaN |
| graham number | 32.97 | 39.01 | -15.47 |
| roic | 0.02 | 0.01 | 72.45 |
| return on tangible assets | 0.0 | 0.01 | -13.55 |
| graham net net | -142.43 | -126.4 | -12.68 |
| working capital | 463524000 | 591369000 | -21.62 |
| tangible asset value | 190689000 | 212520000 | -10.27 |
| net current asset value | -659370000 | -625460000 | -5.42 |
| invested capital | 463524000 | 1231981000 | -62.38 |
| average receivables | 118063500 | 119816500 | -1.46 |
| average payables | 50610500 | 48683500 | 3.96 |
| average inventory | -6400000 | -15733999.5 | 59.32 |
| days sales outstanding | 190.32 | 199.57 | -4.63 |
| days payables outstanding | 171.67 | 133.24 | 28.84 |
| days of inventory on hand | 0 | -33.59 | 100.00 |
| receivables turnover | 0.47 | 0.45 | 4.86 |
| payables turnover | 0.52 | 0.68 | -22.38 |
| inventory turnover | 0 | -2.68 | 100.00 |
| roe | 0.04 | 0.04 | -11.19 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to 0.04 on 2024-09-30 Q3 from 0.04 on 2024-06-30 Q2, representing a change of -11.19%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 10.02 on 2024-09-30 Q3 from 12.51 on 2024-06-30 Q2, representing a change of -19.87%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 5.78 on 2024-09-30 Q3 from 5.09 on 2024-06-30 Q2, representing a change of 13.47%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. A ratio of 2.0 or higher is usually considered risky.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 46.58 on 2024-09-30 Q3 from 33.21 on 2024-06-30 Q2, representing a change of 40.24%. Indicating an increase in the relative valuation of the company's stock.
Positive Sentiment: Discounted Cash Flow value is 448.12 which is higher than current price 192.06, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-12-18 08:00:00
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
Sentiment: Positive
Publish Date: 2024-12-02 16:05:00
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce the results of matters voted on at the Company's Annual General and Special Meeting of shareholders of the Company (the "Shareholders") held this morning at 10:00 AM (Vancouver time) (the "Meeting"). At the Meeting, Shareholders were asked to vote on resolutions approving, among other things, the acquisition by Greenridge Exploration Inc. ("Greenridge") (CSE: GXP) of all of the outstanding and issued common shares of ALX (the "ALX Shares") by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement").
Sentiment: Neutral
Publish Date: 2024-11-14 08:00:00
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development
Sentiment: Positive
Publish Date: 2024-11-12 06:00:24
Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting overall profitability. Management has created value with $154 million in economic earnings since 2019, but ALX remains overvalued with unrealistic growth expectations.
Sentiment: Positive
Publish Date: 2024-11-10 09:00:00
U.S. equity markets soared to record highs this week after President-elect Trump scored a surprisingly decisive election victory, including a likely "trifecta" of Republican legislative control in Congress. The outcome sparked powerful moves across global financial markets as investors priced in a combination of domestic-focused and "pro-growth" economic policies but also reflected concern over deficits and immigration policy. Characteristic of the "Trump trade" dynamic, smaller-cap companies led the surge, outperforming mega-cap technology and international-heavy peers. The S&P Small-Cap 600 soared 9%, outpacing 5% gains from the S&P 500.
Sentiment: Positive
Publish Date: 2024-11-07 16:00:00
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
Sentiment: Positive
Publish Date: 2024-11-07 07:30:00
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce that its management information circular (the "ALX Circular") and related materials (collectively, the "Materials") in connection with the Annual General and Special Meeting (the "Meeting") of its shareholders (the "ALX Shareholders") is now available on ALX's website ( click here to access the Materials) as well as under ALX's profile on SEDAR+ (www.sedarplus.ca). The Company commenced the mailing of the Materials for the Meeting to ALX Shareholders on Tuesday, November 5, 2024.
Sentiment: Positive
Publish Date: 2024-11-04 10:55:32
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago.
Sentiment: Neutral
Publish Date: 2024-11-04 09:16:00
PARAMUS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2024 today and reported:
Sentiment: Positive
Publish Date: 2024-11-01 17:30:00
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers
Sentiment: Positive
Publish Date: 2024-10-30 13:33:00
PARAMUS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 29, 2024 to stockholders of record on November 11, 2024.
Sentiment: Positive
Publish Date: 2024-10-22 13:45:00
PARAMUS, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 4, 2024, before the New York Stock Exchange opens.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
